4Cunha-Vaz J. Lowering the risk of visual impainment and bilndbess [J]. Diabet Med, 1998, 15(Suppl 4):S47-50.
5Fong DS, Ferris FL 3rd, Davis MD, et al. Causes of severevisual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group [J]. Am J Ophthalmol, 1999, 127 (2): 137-141.
6Centers for Disease Control and Prevention. Prevalence and incidence of diabetes mellitus in United States, 1980-1987[J]. MMWR Morb Mortal Wkly Rep,1990,39(45):809-812.
7Valiatti FB, Crispim D, Benfiea C, et al. The role of vascular endothelial growth factor in angiogenesis and diabetic retinopathy [J]. Arq Bras Endocrinol Metabol, 2011, 55(2) : 106-113.
8Mason JO, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy [J]. Am J Ophthalmol, 2006,142 (4) :685-688.
9Ambati J, Chalam KV, Chawla DK, et al. Elevated gamma- aminobutyric acid, glutamate and vascular endothelial growth factor levels in the vitreous of proliferative diabetic retinopathy [J]. Arch Ophthalmol, 1997,15(9) : 1161-1166.
10di Lauro R, De Ruggiero P, di Lauro R, et al. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy [J]. Graefers Arch Clin Exp Ophthalmol, 2010, 248 (6) :785-791.
